Update on Herpes Zoster Vaccine (shingles): Licensure for Persons Aged 50 Through 59 Years, January 11, 2012, 307 (2): 137 — JAMA

"Contraindications to the use of Zostavax remain unchanged. Zostavax should not be given to pregnant women, persons with a primary or acquired immunodeficiency, or to persons with a history of anaphylactic reaction to gelatin, neomycin, or any other component of the vaccine. Herpes zoster vaccine can be administered simultaneously with other indicated vaccines.1"

Apr 2011: Postherpetic Neuralgia: An Overview of the Pathophysiology, Presentation, and Management (shingles)

Postherpetic neuralgia (PHN) presents itself as a frustrating and fascinating subject within the realm of neuropathic pain. With herpes zoster (shingles) affecting roughly 3.4 per 1,000 people, and nearly .49 per 1,000 people developing PHN annually, the subject continues to be a prevalent dilemma in want of further study. Drs. Christopher Gharibo and Carolyn Kim explore the diagnosis, treatment and management of this complicated condition.

Download to read this article in PDF document:
Postherpetic Neuralgia: An Overview of the Pathophysiology, Presentation, and Management

This article is in PDF format and it requires Abobe Reader.

New study alters long-held beliefs about shingles (herpes zoster virus)

HealthNewsReview.org: Shingles Vaccine Looks Like a Safe Bet for Seniors: Study

Avoiding the worst in shingles - media article

"The zoster vaccine has demonstrated benefit in reducing the frequency and severity of zoster in elderly patients. It’s an attenuated vaccine, so should be used with caution in patients who have immunosuppression."

Statement on the Recommended Use of Herpes Zoster Vaccine: An Advisory Committee Statement - Canada Communicable Disease Report (CCDR) Vol.35 ACS-1 - Public Health Agency of Canada